Suggested remit - To appraise the clinical and cost effectiveness of pembrolizumab in combination with carboplatin and paclitaxel or nab-paclitaxel within its marketing authorisation for untreated metastatic squamous non-small-cell lung cancer.
Status In progress
Process STA 2018
ID number 1306

Provisional Schedule

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 22 May 2018 - 20 June 2018

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
28 September 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance